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ABSTRACT
CD22-targeted recombinant immunotoxins (rIT) are active in hairy cell 
leukemia or acute lymphoblastic leukemia (ALL), but not in mantle cell lymphoma 
(MCL) patients. The goal was to enhance rIT efficacy in vivo and to define a strong 
combination treatment. Activity of Moxetumomab pasudotox (Moxe) and LR combined 
with paclitaxel was tested against MCL cell lines in vitro and as bolus doses or 
continuous infusion in xenograft models. In the KOPN-8 ALL xenograft, Moxe or 
paclitaxel alone was active, but all mice died from leukemia; when combined, 60% 
of the mice achieved a sustained complete remission. Against MCL cells in vitro, LR 
was more active than Moxe and the cells had to be exposed to rIT for more than 24 
hours for them to die. To maintain high blood levels in vivo, LR was administered 
continuously by 7-day pumps achieving a well-tolerated steady plasma concentration 
of 45 ng/ml. In JeKo-1 xenografts, continuously administered LR was 14-fold more 
active than bolus doses and the combination with paclitaxel additionally improved 
responses by 135-fold. Maintaining high rIT-plasma levels greatly improves responses 
in the JeKo-1 model and paclitaxel substantially enhances bolus and continuously 
infused rIT, supporting a clinical evaluation against B-cell malignancies.
INTRODUCTION
We have developed recombinant immunotoxins 
(rIT) which consist of an antibody fragment fused to a 
truncated Pseudomonas exotoxin A [1]. The first CD22-
targeting rIT BL22 (CAT-3888) is active against B-cell 
non-Hodgkin lymphoma (B-NHL) cell lines in vitro [2] 
and achieves an objective response rate of 81% in patients 
with hairy cell leukemia (HCL) [3]. However, BL22 
fails to produce objective responses in pediatric B-cell 
acute lymphoblastic leukemia (B-ALL) [4] or mantle 
cell lymphoma (MCL) [3]. The affinity matured BL22-
variant HA22 or Moxetumomab pasudotox (Moxe) [5] is 
10-fold more potent than BL22 in vitro and achieves an 
overall response rate of 86% in HCL patients [6] and of 
33% in pediatric B-ALL [7]. HCL patients treated with 
Moxe regularly develop neutralizing antibodies which 
likely reduce the anti-leukemic activity in these patients 
[6]. To decrease immunogenicity, we generated HA22-
PE24 (named LR) [8] which lacks domain II and therefore 
major B- [9] and T-cell epitopes [10]. In addition, LR is 
more active than Moxe or BL22 against various ALL and 
lymphoma cell lines and against patient-derived chronic 
lymphocytic leukemia (CLL) [8]. LR has not yet been 
developed clinically.
MCL is a rare subtype of B-NHL of 6% [11]. New 
treatment options include the Burton’s Tyrosine kinase 
(BTK)-inhibitor Ibrutinib [12, 13], the proteasome 
inhibitor Bortezomib [14-16], the immune-modulator 
Lenalidomide [17-19], and the mTORC-inhibitor 
Temsirolimus [13, 20] which are active in patients with 
relapsed/refractory MCL; various combinations of these 
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small molecules with current standard treatment regimens 
are in clinical testing [11, 21-23]. Despite recent progress 
in treatment options and the introduction of intensified 
chemotherapy regimens with autologous stem cell 
transplantation leading to a doubling of progression-
free survival of MCL patients over the past two decades, 
most patients still relapse and MCL remains an incurable 
disease [22].
We recently showed that the activity of CD22-
targeting rIT against ALL cells in vitro and in vivo 
improved substantially when the cells were exposed 
longer to CD22-targeting rIT [24]. Because rITs have a 
short plasma half-life in mice [8] and men [7], blood levels 
fall quickly after a bolus dose. The rIT exposure time of 
ALL cells growing in murine bone marrow (BM) achieved 
by bolus doses was too short for them to die; when high 
rIT blood levels were maintained by repeated injections, 
in vivo efficacy was greatly improved [24].
Mesothelin-targeting rITs are enhanced by various 
small molecules [25-27] or the chemotherapeutic drug 
paclitaxel [28-30]. Paclitaxel enhances the efficacy of 
bolus doses of mesothelin-targeted rIT in vivo [28, 29, 
31], which was translated in a new clinical trial testing the 
combination (NCT02810418). Whether in vivo efficacy of 
CD22-targeting rIT is enhanced by paclitaxel has not been 
determined previously.
Here, we tested whether the addition of paclitaxel 
would improve treatment outcome in the KOPN-8 
xenograft model [24]. To extend our studies toward MCL, 
various cell lines were tested in vitro and LR was found to 
be more active than Moxe. The time that MCL cells needed 
to be exposed to either rIT for them to die varied largely 
from hours to days. To enable continuous drug delivery in 
vivo by 7-day osmotic pump, the rIT-formulation buffer 
was optimized to ensure protein stability, which then 
allowed for the comparison of bolus dose and continuous 
administration and finally the combination with paclitaxel 
in a newly established systemic JeKo-1 xenograft model.
RESULTS
Paclitaxel/rIT-combination achieves durable 
remissions in an ALL xenograft model
To search for combination therapies which enhance 
the in vivo efficacy of CD22-targeting rITs, we used our 
recently developed KOPN-8 xenograft model [24]. After 
i.v. injection, the KOPN-8 cells grow in the murine BM 
and three bolus doses of Moxe every other day (QOD) 
reduce the KOPN-8 BM infiltration below the detection 
limit of flow cytometry. However, all mice relapse and 
die from leukemia [24]. To track treatment responses in 
real time, KOPN-8 cells were transduced with luciferase 
and green fluorescent protein (GFP) and single cloned. 
After i.v. injection, the disease burden was measured 
by determining the bioluminescence. In this KOPN-8 
model, the combination of paclitaxel and Moxe improved 
responses greatly (Figure 1A). Before start of treatment 
on day 7, all mice showed a similar bioluminescence 
signal. In accordance with the known KOPN-8 BM 
infiltration [24], the bioluminescence was found in close 
proximity to bones. Untreated mice progressed rapidly 
as shown by a steep increase in bioluminescence. For 
mice receiving a single dose of 25 mg/kg paclitaxel i.p. 
on day 7 bioluminescence increased between days 7 and 
19, but was lower than the bioluminescence of control 
mice on day 19. Three i.v. bolus doses of 0.4 mg/kg Moxe 
QOD given from day 8 resulted in an abrogation of the 
bioluminescence signal on day 19 but the bioluminescence 
recurred in all these mice indicating expected leukemia 
relapse. The mice which had received the combination 
of Moxe and paclitaxel showed an abrogation of the 
bioluminescence on day 19. In mice 2, 6, and 9 on day 
39 and in mouse 8 on day 58 bioluminescence recurred, 
indicating leukemia relapse which was confirmed by flow 
cytometry analysis of the BM post mortem. The remaining 
six mice stayed bioluminescence free until day 130 when 
the experiment was terminated and no evidence was found 
for residual KOPN-8 cells in the murine BM by flow 
cytometry (data not shown).
The time the KOPN-8 bearing mice survived after 
treatment correlated directly with the course of their 
bioluminescence signal (Figure 1B). Untreated mice 
survived on average until day 22, mice receiving paclitaxel 
alone until day 30, and mice receiving Moxe alone until 
day 53. The six mice lacking any bioluminescence after 
receiving the combination lived until the experiment was 
terminated on day 130. We conclude that the combination 
of paclitaxel and Moxe improves responses in the KOPN-
8 xenograft model.
LR is more active than Moxe in vitro
To test the rIT and paclitaxel combination in an 
MCL xenograft model, we first compared Moxe and LR 
for their in vitro activity against MCL cell lines by WST-8 
assays. Table 1 shows that LR was more active than Moxe 
against all MCL cell lines with IC
50
s ranging from 0.3 ng/
ml to 6 ng/ml (6 pmol/l to 120 pmol/l). The LR-activity 
was higher by 1.7-fold against Rec-1, 2.4-fold against 
JeKo-1, 2.4-fold against JVM-2, 3.0-fold against Mino, 
and 3.3-fold against Z-138 (Table 1). The data show that 
the deletion of all but the furin cleavage site of domain 
II results in an increased activity of CD22-targeting rIT 
against MCL cell lines which is in line with the increased 
activity of LR against patient derived CLL [8].
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MCL cell lines need highly variable rIT-exposure 
time for them to die
Whether the activity of rIT against MCL cells 
depends on the time the cells are exposed to rIT was 
tested by treating MCL cell lines with 140 ng/ml Moxe 
or equimolar LR for various times, cells were washed and 
replated in complete medium without rIT and viability 
determined three days after assay initiation, enough time 
for the cells to die if they were exposed to a lethal rIT 
dose. Figure 2 shows that the exposure time needed to kill 
more than 50% of the cells varied among the cell lines 
from less than one hour to three days. Killing of more than 
50% of the Rec-1 cells was reached after less than 1 hour, 
of JeKo-1 or JVM-2 cells after 9 hours, of Mino cells after 
24 hours and of Z-138 cells after 72 hours. In Rec-1 and 
Figure 1:Paclitaxel enhances in vivo efficacy of CD22-targeting immunotoxin in KOPN-8 xenografts. NSG mice bearing 
luciferase positive KOPN-8 cells were treated with a single dose of 25 mg/kg paclitaxel i.p. on day 7, 3 doses of 0.4 mg/kg Moxe QOD from 
day 8, or the combination. A. Bioluminescence signal was measured at the indicated days. All images were taken with identical camera 
settings (binning “medium”, exposure time 1 second). Signal intensity is shown as radiance from 100 (blue) to 30,000 (red). Mice without 
any detectable bioluminescence were imaged a second time using “high sensitivity” camera settings (binning “high”, exposure time 1 
minute). The arrow points towards the “high sensitivity” image of mouse one of the Moxe group. B. Animal survival is shown as a Kaplan 
Meyer curve, the significance was determined by log-rank test. 
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JVM-2 there was no significant difference between Moxe 
and LR, while JeKo-1 (p = 0.01), Mino (p = 0.02), and 
Z-138 (p = 0.03) were killed faster by LR than by Moxe. 
The longer the MCL cells are exposed to rIT in vitro the 
more likely they die. This exposure time varies from hours 
to days.
Continuous administration improves responses 
10-fold
Because rITs have a short serum half-life of 
approximately 15 minutes in mice [8], but JeKo-1 cells 
need more than 9 hours of rIT exposure for 50% of the 
cells to die, we hypothesized that in vivo efficacy may 
improve by maintaining high rIT blood levels. In mice, 
continuous administration can be achieved by implanting 
an osmotic pump into the peritoneal cavity where it 
remains for seven days at body temperature. We tested 
LR stability in the standard rIT-formulation PBS at 37°C. 
The data in Figure 3A show that LR in PBS loses activity 
rapidly. LR-activity fell 2.5-fold below initial activity 
within one day, fell 9-fold within three days, and was not 
detectable after seven days. We empirically tested several 
buffer formulations for their capability to stabilize LR. 
Stabilization was most efficient in the clinically used 
Moxe formulation (32 mM citrate, 0.65% Tween80, 5 
mM EDTA) where LR was stable for up to seven days 
(Figure 3B). LR-activity on day 1 was similar to the 
activity at assay initiation and was less than 2-fold reduced 
by days 3 or 7, respectively. The buffer exchange from 
PBS to citrate-buffer itself did not change LR-activity 
(Supplementary Figure S1). We conclude that LR in the 
citrate buffer is sufficiently stable to treat mice with a 
7-day osmotic pump. 
The steady state plasma concentration reached in 
mice by pump-administrated LR was then determined 
from plasma serial dilutions using WST-8 assays. Over an 
8-day period post-implantation, LR-plasma concentration 
was on average 45 ng/ml (Figure 3C) correlating with an 
area under the curve (AUC) of 350 ng x day/mlPlasma. This 
steady state plasma concentration was higher than the IC
50
 
of any of the MCL cell lines tested.
A systemic JeKo-1 xenograft model was used to test 
whether continuously administered LR was more active 
than bolus doses. Within 14 days after i.v. injection, JeKo-
1 cells grow predominantly in the BM and proliferate at 
later stages also in other organs including the spleen and 
the liver [32]. The data in Figure 3D show that continuous 
infusion substantially increased efficacy of LR compared 
to bolus dose administration. At treatment start defined as 
day 0, the rate of JeKo-1 BM-infiltration as determined by 
flow cytometry was on average 38% and increased to 61% 
by day 9 in untreated mice. Three i.v. bolus doses of 2 mg/
kg LR on days 0, 2, and 4 resulted in an infiltration rate 
of 40% on day 9, which was significantly lower than in 
untreated mice (p < 0.0001), but not different from the rate 
of JeKo-1 BM-infiltration at treatment start. Continuously 
infused LR reduced the JeKo-1 BM-infiltration by 13-fold 
to an infiltration rate of 3% which was significantly lower 
than the infiltration after three bolus doses (p < 0.0001). 
Maintaining continuously high LR blood levels improved 
responses greatly.
Enhancement by paclitaxel is minor in vitro but 
substantial in vivo 
Before testing the combination of pump-
administered LR and paclitaxel in vivo, we determined 
whether paclitaxel enhances LR in vitro by WST8 assays. 
Four of five MCL cell lines were sensitive to paclitaxel 
alone at concentrations achieved in murine organ tissue 
after a single dose of 25 mg/kg (Supplementary Figure S2 
[33]). The sensitive cell lines showed IC
50
s of 2.0 nM for 
JeKo-1, 2.4 nM for Z-138, 4.1 nM for Mino, and 5.8 nM 
for JVM-2, whereas the less sensitive Rec-1 showed an 
IC
50
 of 153 nM. When paclitaxel and LR were combined 
in vitro, activity improved in two of five cell lines (Figure 
4A, Supplementary Figure S3). Paclitaxel enhanced LR-
activity 3.7-fold against Z-138 and 2.4-fold against Jeko-
1, while LR-activity against Rec-1, JVM-2, or Mino 
remained unchanged.
For in vivo testing, JeKo-1-bearing mice were 
implanted with a 7-day osmotic pump on day 0, 14 days 
after tumor inoculation. To allow for wound healing 
after the surgery, paclitaxel was injected i.p. 2 days after 
the pump implantation. Mice were euthanized on day 9 
and their BM analyzed. As shown in Figure 4B, mice at 
treatment start had on average a JeKo-1 BM-infiltration of 
Table 1: Activity of Moxe and LR against MCL cell lines
Moxe-IC50 [ng/ml] LR-IC50 [ng/ml] Fold-Difference* p-value
Rec-1 0.3+/-0.05 0.2+/-0.03 1.7 0.08
Jeko-1 1.2+/-0.1 0.5+/-0.04 2.4 0.002
JVM-2 1.6+/-0.2 0.7+/0.13 2.4 0.01
Mino 2.6+/-0.8 0.9+/-0.15 3.0 0.11
Z-138 6.0+/-1.8 1.9+/-0.5 3.3 0.10
IC
50
 was determined by WST8 assay after exposure to serial dilutions of HA22 or LRGGS for 3 days. *Fold-difference of 
activity was corrected for molecular weight difference between Moxe and LR. Data represents means of three independent 
experiments, error is shown as SEM, p-values were determined by paired t-tests.
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48% which increased to 84% on day 9 in vehicle treated 
mice. Treatment with paclitaxel alone reduced JeKo-1 
BM-infiltration significantly to 76% on day 9 (p = 0.004). 
Compared to treatment initiation, the continuously infused 
LR reduced the JeKo-1 BM-infiltration by 11-fold (p < 
0.0001). Combining the continuously infused LR with 
paclitaxel further decreased the Jeko-1 BM-infiltration to 
0.1% (p < 0.0001). 
To enable a comparison of six independent 
experiments, we determined the fold-change in JeKo-1 
BM infiltration of each of 95 individual mice nine days 
after treatment initiation relatively to the average JeKo-1 
BM infiltration at treatment start within their respective 
experiment (Figure 4C). The data show that vehicle and 
Taxol-treated mice progressed, QOD-treated mice showed 
a stable BM-infiltration, which decreased when LR was 
administered by pump and decreased even further by the 
addition of paclitaxel. To directly compare activity of 
treatment groups, the relative efficacy was mathematically 
determined (Figures 4D-G). Treating mice with a single 
dose of paclitaxel on day 2 was on average 1.15-fold more 
active than vehicle in reducing BM-infiltration on day 9 (p 
= 0.05, Figure 4D). Compared to infiltration at treatment 
start, three bolus doses LR QOD did not change the JeKo-
1 BM-infiltration (p = 0.89, Figure 4E). Exchanging bolus 
doses with continuous administration resulted on average 
in a 14-fold increased efficacy (p < 0.0001, Figure 4F). 
Therefore, a well-tolerated total amount of 84 µg LR given 
by continuous infusion is substantially more active than 
the 120 µg LR given as three bolus doses QOD.
By the addition of paclitaxel to continuously 
administered LR, the responses improved on average by 
135-fold over pump administration alone (p = 0.0005, 
Figure 4G). Of note, in the BM of all mice that had 
received the combination, viable JeKo-1 cells were still 
detectable on day 9 by flow cytometry when experiments 
were terminated. Due to pump properties, the experiments 
had to be stopped 10 days after implantation and therefore, 
effects of the treatment on animal survival were not 
determined. The efficacy of continuously infused LR is 
substantially enhanced by paclitaxel.
DISCUSSION
Searching for a molecule that enhances CD22-
targeting rIT in vivo, we found the combination with 
Figure 2: The time for rITs to reach maximal cytotoxic activity is highly variable. Indicated MCL cell lines were exposed 
to 140 ng/ml Moxe (black) or equimolar LR (grey) for various times, washed, replated, and cell-viability determined after a total of 3 
days. Viability of untreated cells was set to 100%, 0% was defined as real 0. Each bar represents the average percent living cells of three 
independent experiments, error is shown as SEM.
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Figure 3: LR in citrate buffer is stable, pump-administration achieves high serum levels increasing activity by 10-fold. 
LR at 2 mg/ml in standard buffer PBS A. or citrate buffer B. were incubated at 37°C for the indicated times, frozen at -80°C, and activity 
of each sample determined by WST8 assays. Activity of an immediately frozen aliquot (day 0) was set to 1 to which the remainder were 
normalized. Bars indicate average normalized IC
50
, errors are shown as SEM. C. Mice were implanted with an ALZET osmotic pump 
containing LR at 1 mg/ml in citrate buffer on day 0. From day 1, blood was collected, the plasma separated by centrifugation, and the LR 
concentration was determined by WST8 assays. Each symbol represents the average LR plasma concentration of 3 mice, except day 6 
(only 2 mice), error is shown as SEM (except day 6), AUC as determined by Graph Pad Prism, v.6.01. The average plasma concentration 
is indicated as a dashed line. D. Some mice bearing systemic Jeko-1 were euthanized on day 0 and the JeKo-1 BM infiltration determined. 
The remainder were either implanted with a 7-day ALZET osmotic pump containing 1 mg/ml LR in citrate buffer and a pump rate of 0.5 
µl/h, treated with 3 doses of 2.0 mg/kg LR QOD i.v. from day 0, or treated with vehicle. The treated mice were sacrificed on day 9 and their 
BM was analyzed for JeKo-1 cells by flow cytometry. Symbols indicate individual mice, lines represent mean JeKo-1 BM-infiltration, error 
as SEM. Significance determined by unpaired t-test as ns (not significant) or as indicated.
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paclitaxel to eradicate leukemia cells in 60% of KOPN-8-
bearing mice which survive tumor-free for months. With 
the goal to test the efficacy of this combination in an MCL 
xenograft, we found in vitro (i) that LR was more active 
than Moxe against MCL cells and that (ii) MCL cells had 
to be exposed to CD22-targeting rITs for a highly variable 
time for them to die. Due to a short serum half-life of 
15 - 20 minutes, rIT plasma concentrations after an i.v. 
bolus dose fall within less than 2 hours to inactive levels. 
In accord with the needed exposure time of 9 hours for 
50% of the Jeko-1 cells to die in vitro, response to CD22-
targeting rIT improves more than 10-fold in the JeKo-1 
xenograft model when i.v. bolus doses are exchanged for 
continuous infusion by osmotic pumps. The addition of 
paclitaxel to the optimized continuous rIT-administration 
increases efficacy more than 100-fold over continuous LR 
alone.
An in vivo enhancement of mesothelin-targeting 
rITs by paclitaxel has been described in xenograft models 
of solid tumors including the mesothelin-expressing 
pancreatic cancer cell line KLM-1 [28], breast cancer 
cell line HCC-70, gastric cancer cell line MKN-28 [29], 
and the cervical cancer cell line KB [31]. Similar to our 
findings with CD22-targeting rIT, enhancing effects for 
paclitaxel have been shown for mesothelin-targeting 
rITs with domain II [31] and without [28, 29], resulting 
in a new clinical trial testing the efficacy of the LMB-
100 in combination with Nab-paclitaxel for patients with 
mesothelin expressing solid tumors (NCT02810418). 
Taken together the data suggest that paclitaxel enhances 
rITs in vivo independent from the target or domain II-
status. In the KOPN-8 model, CD22-targeting rIT alone 
reduces tumor burden below the detection level by 
bioluminescence or flow cytometry and only a few cells 
remain, presumably responsible for late relapse and animal 
death [24]. It is possible that paclitaxel kills these few 
remaining cells specifically shown here. An alternative 
explanation which is supported by the JeKo-1 data and 
the data on mesothelin-targeted rITs is that the two drugs 
have a highly synergistic mechanism in killing the target 
cells and the few remaining cells in the KOPN-8 model 
are sensitized to LR.
We currently do not understand the mechanism 
behind the exceptional in vivo synergy of paclitaxel and 
rITs. In vivo results with the KB tumors suggested that 
reduced shedding of surface mesothelin by the paclitaxel 
treatment reduced decoy receptors produced by the tumor, 
ultimately increasing delivery of rIT [31]. Improvement 
of drug delivery after paclitaxel treatment was not shown 
in a KLM-1 model [28], making the reduction of decoy 
receptors as the reason for improved rIT-efficacy here 
unlikely. That only a little CD22 is shed from the cell 
surface [34] also argues against reduced shedding as a 
major mechanism for the in vivo enhancement of CD22-
targeted rIT. While the enhancement by paclitaxel in 
vivo is substantial, in vitro effects for the enhancement 
of Mesothelin-targeting rITs have been small or absent 
[35]. We similarly find a comparably small two to three-
fold enhancement of immunotoxin activity against only 
two of the five MCL cell lines in vitro. Immunotoxins 
arrest protein synthesis, ultimately leading to a fall of 
the anti-apoptotic protein MCL1, which destabilizes 
mitochondria and activates the intrinsic apoptosis [36], 
while paclitaxel activates the extrinsic apoptosis [37]. 
Both apoptosis pathways converge in late apoptotic 
events which may explain the in vitro synergy. Alterations 
in the expression levels of the regulators of programmed 
cell death, the Bcl-2 family proteins are common in 
hematologic malignancies [38] which may explain the 
variation in the rIT-enhancing effects of paclitaxel in vitro 
[37]. That the >100-fold enhancement of continuously 
administered LR in JeKo-1-bearing mice by paclitaxel is 
distinctively higher than the only two-fold enhancement 
in vitro suggests a distinct mechanism responsible for 
the exceptional in vivo synergy and indicates that in vitro 
tests may not be predictive. The in vivo mechanism of the 
paclitaxel induced rIT-enhancement remains unexplained.
In the first clinical trial, the CD22-targeting rIT 
BL22 achieved a high rate of objective responses in HCL 
patients but failed to show activity in CLL, follicular 
lymphoma, MCL [3], and ALL [4]. Objective responses 
in ALL patients increased after increasing the affinity to 
CD22 by 10-fold [7], but were still below the expected 
response rate [39]. Recent data from ALL xenograft 
models led to the concept that responses might improve 
if high rIT blood levels are maintained longer [24]. The 
previous data suggest that differences in the complex 
trafficking of Pseudomonas exotoxin A [40] may explain 
the differences in the time cells need to be exposed to 
immunotoxin for them to die. We describe here that CD22-
targeting rITs show an exposure time dependent activity 
also against MCL cells in vitro and translate these findings 
into an MCL xenograft model. Because of the rapidly 
falling rIT blood levels after a bolus dose in patients, 
the data suggest that responses in B-NHL patients might 
improve if rIT was given continuously.
In summary, continuous infusion as opposed 
to bolus doses substantially improves response in an 
MCL xenograft model which corroborates our previous 
findings in ALL, emphasizing that a change of the current 
bolus dose administration to continuous infusion may 
substantially improve response rates in MCL patients. 
The exceptionally strong synergy between paclitaxel and 
CD22-targeting rIT makes this combination a promising 
candidate for future clinical testing.
MATERIALS AND METHODS
Reagents
Moxe [5] and LR [8] were produced as previously 
described. For the last step in the rIT purification process 
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Figure 4: Minor in vitro enhancement contrasts with a substantial improvement of in vivo efficacy by the addition 
of paclitaxel. A. MCL cell lines were treated with LR and various concentrations of paclitaxel; after 72 hours, cells were stained with 
Annexin V-PE and 7-AAD and viability was determined by flow cytometry. The bars represent the mean IC
50
-fold changes when paclitaxel 
was added. Fold-change values were only included if paclitaxel alone reduced cell viability by at least 15% (indicating that paclitaxel at 
this concentration was active) but not more than 85% (non-linear regression becomes unreliable below this threshold). The fold-changes 
were summarized from at least three independent experiments; errors as SEM, p-values were determined by unpaired t-tests. B. Some 
JeKo-1 bearing mice were analyzed for BM infiltration at treatment start on day 0 and the remainder treated with either vehicle, a single 
dose of 25 mg/kg paclitaxel i.p. on day 2, implanted with a 7-day ALZET osmotic pump containing 1 mg/ml LR in citrate buffer from 
day 0, or the combination of pump and paclitaxel. Symbols indicate individual mice, lines represent mean JeKo-1 BM-infiltration, errors 
as SEM, p-values were determined by unpaired t-test. C. The graph summarizes 95 mice from a total of 6 individual experiments. Each 
bar represents one mouse and its fold-change of JeKo-1 BM infiltration 9 days after the indicated treatment relative to the average BM-
infiltration at the treatment start of the corresponding experiment control on day 0. The color indicates treatment type as vehicle (black), 
Taxol mono (blue), 2.0 mg/kg LR i.v. QOD (yellow), LR 0.6 mg/kg/day by 7-day pump (green), and the combination of LR by pump and 
paclitaxel (red). D.-G. To determine the relative efficacy, the average BM-infiltration in the indicated groups was set to 1 and the relative 
fold-change was determined as (D) vehicle treated on day 9 (D9) vs. paclitaxel (D9), as (E) day 0 vs. QOD (D9), (F) as QOD (D9) vs. 
pump-administrated LR (D9), and as (G) pump-administrated LR without vs. with paclitaxel (D9). Color codes in (D-G) are as indicated in 
(C), the bars show the mean relative fold-change, errors are shown as SEM, p-values were determined by unpaired t-tests.
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[42], the size exclusion chromatography, elution buffer 
PBS, pH 7.4 was changed to a citrate formulation (32 mM 
citrate pH 6.0, 5 mM EDTA, 0.65% Tween 80). Clinical 
grade paclitaxel in Cremophore (6 mg/ml) was purchased 
from Teva Pharmaceuticals (#00703-4764-01). For in vitro 
application, paclitaxel was diluted in RPMI to indicated 
concentrations and for in vivo application it was diluted to 
1.25 mg/ml in PBS, pH 7.4.
Cell lines
The Jeko-1, JVM-2, and REC-1 cells were described 
previously [43]. The Mino and Z-138 cells were kindly 
provided by Dr. Louis Staudt, NCI/NIH. The B-cell 
precursor (BCP-) ALL cell line KOPN-8 [24] was 
transduced with a luciferase and GFP containing lentivirus, 
sorted for the top 5% GFP expression twice, and single-
cloned. All cells were grown in RPMI supplemented with 
10% fetal bovine serum, 100 U penicillin, and 100 mg 
streptomycin (Invitrogen).
Cell assays
Cytotoxicity was determined by WST-8 (Dojindo 
Molecular Technologies, Rockville, MD, #CK04-20) 
as described [26]. 5,000 cells/well were incubated with 
various rIT concentrations for 72 hours. WST-8 reagent 
was added, absorbance was measured 2 hours later, values 
were normalized between Cycloheximide (10 μg/ml 
final, Sigma-Aldrich, St. Louis, MO, #C4859-1ML) and 
untreated control and, non-linear regression to obtain IC
50
 
concentrations was done using GraphPad Prism v6.01.
For in vitro apoptosis assays by flow cytometry, 
1 million cells/ml were incubated with 2.8 nM rIT for 
various times, cells washed twice after the indicated 
incubation times, resuspended in complete RPMI, and 
transferred to a new plate. Seventy-two hours after assay 
initiation, cells were stained with 7-AAD/Annexin-PE, 
and measured with a FACS Calibur (BD). Results were 
analyzed with FlowJo software (Tree Star).
Stability testing
LR in PBS or in Citrate buffer was concentrated to 
1 mg/ml using Amicon Ultracell spin columns (Millipore, 
#UFC803024). To test for stability at 37°C, tubes were 
incubated in a heating block for indicated times and 
aliquots frozen at -80°C until used. The remaining rIT-
activity was determined by WST8 assays.
Animal studies
Animals were handled according to NIH guidelines; 
studies were approved by the NCI Animal Care and Use 
Committee.
Ten million JeKo-1 or five million KOPN-8 cells 
were injected on Day 1 via tail vein into 6- to 8-week-
old NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ). One 
mg/ml LR in citrate buffer was loaded into 7-day ALZET 
osmotic pumps dispensing at 0.5 µl/h. The pumps were 
surgically implanted into the peritoneal cavity following 
manufacturer’s instructions. rIT was i.v. injected as three 
bolus doses of 0.4 mg/kg Moxe QOD or 2.0 mg/kg LR 
QOD. Paclitaxel was given as a single dose of 25 mg/kg 
paclitaxel i.p. To assess treatment responses, mice were 
euthanized 10 days after osmotic pump implantation. BM 
was extracted by flushing femurs. Mouse-derived tissue 
was Fc-receptor blocked with anti-murine CD16/32, 
JeKo-1 cells were stained with anti-human-CD20-FITC, 
viability was determined using 7-AAD, and cells were 
analyzed on a FACS Calibur.
To measure the rIT plasma concentration, mice 
were implanted with osmotic pumps and two groups of 
three mice each were bled alternatingly QOD by puncture 
of the mandibular vein. Thirty µl blood/mouse/puncture 
was collected in heparinized tubes, plasma separated by 
centrifugation, and stored at -80 °C until used. Thawed, 
plasma samples were serial diluted in RPMI and tested 
for cytotoxic activity against Rec-1 cells by WST-8. The 
plasma dilution factor at which 50% Rec-1 cells were 
growth inhibited was determined by non-linear regression 
and the corresponding LR plasma concentration was 
extrapolated from a standard curve generated by treating 
Rec-1 with serial dilutions of LR.
Luciferase imaging
D-luciferin (150 mg/kg VivoGlo, Promega, # P1043) 
was injected i.p., mice anesthetized with Isoflurane, and 
images taken 5 minutes after injection using a Xenogen 
IVIS-100 (Caliper).
Statistics
Statistical analyses were performed with Graph Pad 
Prism v6.01 as paired or unpaired t-tests as indicated and 
as log-rank tests for animal survival.
Abbreviations
ALL- Acute lymphoblastic leukemia, AUC-area 
under the curve, B-ALL-B-cell ALL, BCP-ALL-B-cell 
precursor ALL , BM- bone marrow , B-NHL-B cell non 
Hodgkin’s lymphoma, BTK-Bruton’s Tyrosine kinase 
, CLL-chronic lymphocytic leukemia , GFP-green 
fluorescent protein , HCL- hairy cell leukemia , MCL- 
mantle cell lymphoma , Moxe-Moxetumomab pasudotox, 
QOD-every other day, rIT-recombinant immunotoxin.
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